{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:34:26Z","timestamp":1791477266860,"version":"4.3.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,7,15]],"date-time":"2016-07-15T00:00:00Z","timestamp":1468540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,7,15]],"date-time":"2016-07-15T00:00:00Z","timestamp":1468540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["16lk0201021h0004"],"award-info":[{"award-number":["16lk0201021h0004"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s10157-016-1313-5","type":"journal-article","created":{"date-parts":[[2016,7,15]],"date-time":"2016-07-15T11:52:42Z","timestamp":1468583562000},"page":"193-202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Rituximab for nephrotic syndrome in children"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0378-8174","authenticated-orcid":false,"given":"Kazumoto","family":"Iijima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Sako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kandai","family":"Nozu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,15]]},"reference":[{"key":"1313_CR1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/ki.1978.23","volume":"13","author":"International Study of Kidney Disease in Children","year":"1978","unstructured":"International Study of Kidney Disease in Children. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int. 1978;13:159\u201365.","journal-title":"Kidney Int"},{"key":"1313_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0022-3476(81)80760-3","volume":"98","author":"International Study of Kidney Disease in Children","year":"1981","unstructured":"International Study of Kidney Disease in Children. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. J Pediatr. 1981;98:561\u20134.","journal-title":"J Pediatr"},{"key":"1313_CR3","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/S0022-3476(88)80570-5","volume":"113","author":"SL Schulman","year":"1988","unstructured":"Schulman SL, Kaiser BA, Polinsky MS, et al. Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns. J Pediatr. 1988;113:996\u20131001.","journal-title":"J Pediatr"},{"key":"1313_CR4","doi-asserted-by":"publisher","unstructured":"Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst Rev. 2013. Art. No. CD002290, Issue 10. doi: 10.1002\/14651858.CD002290.pub4 .","DOI":"10.1002\/14651858.CD002290.pub4"},{"key":"1313_CR5","doi-asserted-by":"publisher","unstructured":"Hodson EM, Willis NS, Craig JC. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev 2010. Art. No. CD003594, Issue 11. doi: 10.1002\/14651858.CD003594.pub4 .","DOI":"10.1002\/14651858.CD003594.pub4"},{"key":"1313_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s10157-014-1030-x","volume":"19","author":"K Ishikura","year":"2015","unstructured":"Ishikura K, Matsumoto S, Sako M, et al. Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy. Clin Exp Nephrol. 2015;19:6\u201333.","journal-title":"Clin Exp Nephrol"},{"key":"1313_CR7","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/ki.2008.24","volume":"73","author":"K Ishikura","year":"2008","unstructured":"Ishikura K, Ikeda M, Hattori S, et al. Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. Kidney Int. 2008;73:1167\u201373.","journal-title":"Kidney Int"},{"key":"1313_CR8","doi-asserted-by":"crossref","unstructured":"Ishikura K, Yoshikawa N, Hattori S, et al.; For Japanese Study Group of Renal Disease in Children. Treatment with microemulsified cyclosporine in children with frequently relapsing nephrotic syndrome. Nephrol Dial Transpl. 2010;25:3956\u201362.","DOI":"10.1093\/ndt\/gfq318"},{"key":"1313_CR9","doi-asserted-by":"crossref","unstructured":"Hamasaki Y, Yoshikawa N, Hattori S, et al.; Japanese Study Group of Renal Disease. Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2009;24:2177\u201385.","DOI":"10.1007\/s00467-009-1264-0"},{"key":"1313_CR10","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1046\/j.1523-1755.2002.00303.x","volume":"61","author":"K Iijima","year":"2002","unstructured":"Iijima K, Hamahira K, Tanaka R, et al. Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int. 2002;61:1801\u20135.","journal-title":"Kidney Int"},{"key":"1313_CR11","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384:1273\u201381.","journal-title":"Lancet"},{"key":"1313_CR12","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00467-014-2765-z","volume":"29","author":"K Kamei","year":"2014","unstructured":"Kamei K, Okada M, Sato M, Fujimaru T, et al. Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2014;29:1181\u20137.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"1313_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s40124-014-0065-5","volume":"3","author":"K Iijima","year":"2015","unstructured":"Iijima K, Sako M, Nozu K. Rituximab treatment for nephrotic syndrome in children. Curr Pediatr Rep. 2015;3(1):71\u20137.","journal-title":"Curr Pediatr Rep"},{"key":"1313_CR14","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S0140-6736(74)91880-7","volume":"2","author":"RJ Shalhoub","year":"1974","unstructured":"Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet. 1974;2:556\u201360.","journal-title":"Lancet"},{"key":"1313_CR15","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1007\/s00467-009-1214-x","volume":"24","author":"C Araya","year":"2009","unstructured":"Araya C, Diaz L, Wasserfall C, et al. T regulatory cell function in idiopathic minimal lesion nephrotic syndrome. Pediatr Nephrol. 2009;24:1691\u20138.","journal-title":"Pediatr Nephrol"},{"key":"1313_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1681\/ASN.2007111244","volume":"20","author":"L Le Berre","year":"2009","unstructured":"Le Berre L, Bruneau S, Naulet J, et al. Induction of T regulatory cells attenuates idiopathic nephrotic syndrome. J Am Soc Nephrol. 2009;20:57\u201367.","journal-title":"J Am Soc Nephrol"},{"key":"1313_CR17","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","volume":"112","author":"R Stasi","year":"2008","unstructured":"Stasi R, Cooper N, Del Poeta G, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood. 2008;112:1147\u201350.","journal-title":"Blood"},{"key":"1313_CR18","doi-asserted-by":"publisher","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","volume":"3","author":"A Fornoni","year":"2011","unstructured":"Fornoni A, Sageshima J, Wei C, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3:85ra46.","journal-title":"Sci Transl Med"},{"key":"1313_CR19","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1007\/s00467-005-2013-7","volume":"20","author":"K Nozu","year":"2005","unstructured":"Nozu K, Iijima K, Fujisawa M, et al. Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol. 2005;20:1660\u20133.","journal-title":"Pediatr Nephrol"},{"key":"1313_CR20","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1600-6143.2007.02021.x","volume":"8","author":"JM Yabu","year":"2008","unstructured":"Yabu JM, Ho B, Scandling JD, Vincenti F. Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant. 2008;8:222\u20137.","journal-title":"Am J Transplant"},{"key":"1313_CR21","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00467-009-1376-6","volume":"25","author":"A Prytu\u0142a","year":"2010","unstructured":"Prytu\u0142a A, Iijima K, Kamei K, et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol. 2010;25:461\u20138.","journal-title":"Pediatr Nephrol"},{"key":"1313_CR22","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00467-012-2314-6","volume":"28","author":"J Kumar","year":"2013","unstructured":"Kumar J, Shatat IF, Skversky AL, et al. Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis. Pediatr Nephrol. 2013;28:333\u20138.","journal-title":"Pediatr Nephrol"},{"key":"1313_CR23","doi-asserted-by":"publisher","first-page":"374213","DOI":"10.1155\/2011\/374213","volume":"2011","author":"CE Araya","year":"2011","unstructured":"Araya CE, Dharnidharka VR. The factors that may predict response to rituximab therapy in recurrent focal segmental glomerulosclerosis: a systematic review. J Transplant. 2011;2011:374213.","journal-title":"J Transplant"},{"key":"1313_CR24","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1056\/NEJMc063706","volume":"356","author":"A Bagga","year":"2007","unstructured":"Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med. 2007;356:2751\u20132.","journal-title":"N Engl J Med"},{"key":"1313_CR25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00467-007-0640-x","volume":"23","author":"M Nakayama","year":"2008","unstructured":"Nakayama M, Kamei K, Nozu K, et al. Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol. 2008;23:481\u20135.","journal-title":"Pediatr Nephrol"},{"key":"1313_CR26","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.2215\/CJN.03470410","volume":"5","author":"A Gulati","year":"2010","unstructured":"Gulati A, Sinha A, Jordan SC, et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol. 2010;5:2207\u201312.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1313_CR27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00467-012-2319-1","volume":"28","author":"S Ito","year":"2013","unstructured":"Ito S, Kamei K, Ogura M, et al. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatr Nephrol. 2013;28:257\u201364.","journal-title":"Pediatr Nephrol"},{"key":"1313_CR28","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1681\/ASN.2011080775","volume":"23","author":"A Magnasco","year":"2012","unstructured":"Magnasco A, Ravani P, Edefonti A, et al. Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol. 2012;23:1117\u201324.","journal-title":"J Am Soc Nephrol"},{"key":"1313_CR29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/ndt\/gfu267","volume":"30","author":"A Sinha","year":"2015","unstructured":"Sinha A, Bhatia D, Gulati A, et al. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome. Nephrol Dial Transplant. 2015;30:96\u2013106.","journal-title":"Nephrol Dial Transplant"},{"key":"1313_CR30","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s00467-004-1434-z","volume":"19","author":"K Benz","year":"2004","unstructured":"Benz K, D\u00f6tsch J, Rascher W, Stachel D. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol. 2004;19:794\u20137.","journal-title":"Pediatr Nephrol"},{"key":"1313_CR31","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1007\/s00467-006-0228-x","volume":"21","author":"RD Gilbert","year":"2006","unstructured":"Gilbert RD, Hulse E, Rigden S. Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol. 2006;21:1698\u2013700.","journal-title":"Pediatr Nephrol"},{"key":"1313_CR32","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00467-008-0814-1","volume":"23","author":"V Guigonis","year":"2008","unstructured":"Guigonis V, Dallocchio A, Baudouin V, et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol. 2008;23:1269\u201379.","journal-title":"Pediatr Nephrol"},{"key":"1313_CR33","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","volume":"24","author":"K Kamei","year":"2009","unstructured":"Kamei K, Ito S, Nozu K, et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol. 2009;24:1321\u20138.","journal-title":"Pediatr Nephrol"},{"key":"1313_CR34","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ki.2013.211","volume":"84","author":"P Ravani","year":"2013","unstructured":"Ravani P, Ponticelli A, Siciliano C, et al. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int. 2013;84:1025\u201333.","journal-title":"Kidney Int"},{"key":"1313_CR35","doi-asserted-by":"crossref","unstructured":"Ruggenenti P, Ruggiero B, Cravedi P, et al.; Rituximab in Nephrotic Syndrome of Steroid-Dependent or Frequently Relapsing Minimal Change Disease Or Focal Segmental Glomerulosclerosis (NEMO) Study Group. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol. 2014;25:850\u201363.","DOI":"10.1681\/ASN.2013030251"},{"key":"1313_CR36","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2215\/CJN.09421010","volume":"6","author":"P Ravani","year":"2011","unstructured":"Ravani P, Magnasco A, Edefonti A, et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011;6:1308\u201315.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1313_CR37","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1093\/ndt\/gfr548","volume":"27","author":"MJ Kemper","year":"2012","unstructured":"Kemper MJ, Gellermann J, Habbig S, et al. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2012;27:1910\u20135.","journal-title":"Nephrol Dial Transplant"},{"key":"1313_CR38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00467-015-3197-0","volume":"31","author":"K Kamei","year":"2016","unstructured":"Kamei K, Ogura M, Sato M, et al. Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab. Pediatr Nephrol. 2016;31:89\u201395 (Erratum in: Pediatr Nephrol. 2016;31(1):167).","journal-title":"Pediatr Nephrol"},{"key":"1313_CR39","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00467-009-1377-5","volume":"25","author":"S Fujinaga","year":"2010","unstructured":"Fujinaga S, Hirano D, Nishizaki N, et al. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol. 2010;25:539\u201344.","journal-title":"Pediatr Nephrol"},{"key":"1313_CR40","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1681\/ASN.2015050523","volume":"27","author":"M Colucci","year":"2016","unstructured":"Colucci M, Carsetti R, Cascioli S, et al. B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome. J Am Soc Nephrol. 2016;27:1811\u201322.","journal-title":"J Am Soc Nephrol"},{"key":"1313_CR41","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1681\/ASN.2014080799","volume":"26","author":"P Ravani","year":"2015","unstructured":"Ravani P, Rossi R, Bonanni A, et al. Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol. 2015;26:2259\u201366.","journal-title":"J Am Soc Nephrol"},{"key":"1313_CR42","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1016\/j.krcp.2014.05.017","volume":"33","author":"YH Ahn","year":"2014","unstructured":"Ahn YH, Kang HG, Kim SH, et al. Efficacy and safety of rituximab in children with refractory nephrotic syndrome; a multicenter clinical trial. (Abstract) Kidney Res Clin Pract. 2014;33:A1.","journal-title":"(Abstract) Kidney Res Clin Pract"},{"key":"1313_CR43","unstructured":"Rituxan\u00ae Injection 10\u00a0mg\/mL Early Postmarketing Phase Vigilance Report, http:\/\/www.zenyaku.co.jp\/iyaku\/doctor\/rituxan\/survey\/nephrotic\/pdf\/report_150601.pdf . Accessed 10 May 2016."},{"key":"1313_CR44","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1517\/14740338.4.3.599","volume":"4","author":"Y Tsutsumi","year":"2005","unstructured":"Tsutsumi Y, Kanamori H, Mori A, et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf. 2005;4:599\u2013608.","journal-title":"Expert Opin Drug Saf"},{"key":"1313_CR45","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaut.2007.11.013","volume":"30","author":"EJ Boren","year":"2008","unstructured":"Boren EJ, Cheema GS, Naguwa SM, et al. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun. 2008;30:90\u20138.","journal-title":"J Autoimmun"},{"key":"1313_CR46","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s00467-009-1195-9","volume":"24","author":"MC Chaumais","year":"2009","unstructured":"Chaumais MC, Garnier A, Chalard F, et al. Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol. 2009;24:1753\u20135.","journal-title":"Pediatr Nephrol"},{"key":"1313_CR47","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s00467-013-2485-9","volume":"28","author":"AL Sellier-Leclerc","year":"2013","unstructured":"Sellier-Leclerc AL, Belli E, Gu\u00e9rin V, et al. Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome. Pediatr Nephrol. 2013;28:1875\u20139.","journal-title":"Pediatr Nephrol"},{"key":"1313_CR48","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1542\/peds.2009-3395","volume":"126","author":"DS Ardelean","year":"2010","unstructured":"Ardelean DS, Gonska T, Wires S, et al. Severe ulcerative colitis after rituximab therapy. Pediatrics. 2010;126:e243\u20136.","journal-title":"Pediatrics"},{"key":"1313_CR49","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/ndt\/gfu258","volume":"30","author":"K Kamei","year":"2015","unstructured":"Kamei K, Takahashi M, Fuyama M, et al. Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature. Nephrol Dial Transplant. 2015;30:91\u20136.","journal-title":"Nephrol Dial Transplant"},{"key":"1313_CR50","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s00467-014-2794-7","volume":"29","author":"YH Ahn","year":"2014","unstructured":"Ahn YH, Kang HG, Lee JM, et al. Development of antirituximab antibodies in children with nephrotic syndrome. Pediatr Nephrol. 2014;29:1461\u20134.","journal-title":"Pediatr Nephrol"},{"key":"1313_CR51","doi-asserted-by":"publisher","first-page":"R75","DOI":"10.1186\/ar3337","volume":"13","author":"HP Tony","year":"2011","unstructured":"Tony HP, Burmester G, Schulze-Koops H, et al. GRAID investigators. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther. 2011;13:R75.","journal-title":"Arthritis Res Ther"},{"key":"1313_CR52","unstructured":"Current status of patient registration for Rituxan\u00ae Injection drug use-results survey [complicated nephrotic syndrome (frequently relapsing and steroid-dependent)] http:\/\/www.zenyaku.co.jp\/iyaku\/doctor\/rituxan\/survey\/nephrotic\/pdf\/currentstatus_160427.pdf . Accessed 10 May 2016."},{"key":"1313_CR53","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00467-010-1465-6","volume":"25","author":"AL Sellier-Leclerc","year":"2010","unstructured":"Sellier-Leclerc AL, Macher MA, Loirat C, et al. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2010;25:1109\u201315.","journal-title":"Pediatr Nephrol"},{"key":"1313_CR54","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1159\/000356439","volume":"38","author":"T Kimata","year":"2013","unstructured":"Kimata T, Hasui M, Kino J, et al. Novel use of rituximab for steroid-dependent nephrotic syndrome in children. Am J Nephrol. 2013;38:483\u20138.","journal-title":"Am J Nephrol"},{"key":"1313_CR55","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1007\/s00467-011-1886-x","volume":"26","author":"S Ito","year":"2011","unstructured":"Ito S, Kamei K, Ogura M, et al. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2011;26:1823\u20138.","journal-title":"Pediatr Nephrol"},{"key":"1313_CR56","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMc1308488","volume":"370","author":"B Basu","year":"2014","unstructured":"Basu B. Ofatumumab for rituximab-resistant nephrotic syndrome. N Engl J Med. 2014;370:1268\u201370.","journal-title":"N Engl J Med"},{"key":"1313_CR57","first-page":"2015","volume":"16","author":"A Bonanni","year":"2015","unstructured":"Bonanni A, Rossi R, Murtas C, et al. Low-dose ofatumumab for rituximab-resistant nephrotic syndrome. BMJ Case Rep. 2015;16:2015.","journal-title":"BMJ Case Rep"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-016-1313-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-016-1313-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-016-1313-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-016-1313-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T06:41:06Z","timestamp":1692427266000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-016-1313-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,15]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["1313"],"URL":"https:\/\/doi.org\/10.1007\/s10157-016-1313-5","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,15]]},"assertion":[{"value":"25 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is a review article, and does not contain any study involving human participants or animals by the authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Kazumoto Iijima has received Grants from Japan Agency for Medical Research and Development (16lk0201021h0004), and from Japan Medical Association Center for Clinical Trials (CCT-B-2001), personal fees for Safety Review Committee and lecture from Zenyaku Kogyo Co., Ltd., and lecture and manuscript fees from Chugai Pharmaceutical Co., Ltd., during the conduct of the study. KI has also has received grants from Novartis Pharma K.K., Japan Blood Product Organization, Pfizer Japan, Inc., Kyowa Hakko Kirin Co., Ltd., AbbVie LLC, JCR Pharmaceuticals Co., Ltd., Daiichi Sankyo, Co., Ltd., Genzyme Japan K.K., Teijin Pharma Ltd., Miyarisan Pharmaceutical Co., Ltd., CSL Behring, Novo Nordisk Pharma Ltd., AIR WATER MEDICAL Inc., and Astellas Pharma Inc., Lecture fees from Pfizer Japan, Inc., Asahi Kasei Pharma Corp., Kowa Pharmaceutical Co., Ltd., MSD, ALEXION Pharmaceuticals, AstraZeneca K.K., Meiji Seika Pharma Co., Ltd., Novartis Pharma K.K., Daiichi Sankyo, Co., Ltd., Springer Japan, Medical Review Co. Ltd., Boehringer Ingelheim, and NIKKEI RADIO BROADCASTING CORPORATION, and consulting fees from Astellas Pharma Inc., ONO PHARMACEUTICAL CO., LTD. and Takeda Pharmaceutical Company Limited, outside the submitted work. Mayumi Sako has received personal fees for Safety Review Committee and lecture from Zenyaku Kogyo Co., Ltd. during the conduct of the study. Kandai Nozu has received lecture fees from Taisho Pharma and Novartis Pharma outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}